FasR antibodies and methods of use
Provided herein are an exogenous antibody that binds selectively to a misfolded form of human FasR, and methods and uses for said antibody. Specifically disclosed is the antibody designated AMF 3a-118 which selectively binds the peptide represented by LHHDGQFCH (SEQ ID NO:2) and the antibody designated AMF 3d-19 which selectively binds the peptide represented by NSTVCEH (SEQ ID NO:5).
1. An antibody or fragment thereof that binds selectively to a misfolded form of human Fas receptor (FasR), wherein the antibody or fragment thereof binds to an epitope comprising at least 5 contiguous residues of LHHDGQFCH (SEQ ID No. 2) of the misfolded human FasR, the antibody comprising a heavy chain and a light chain, each chain having a constant region and a variable region, each variable region comprising framework regions and complementarity determining regions (CDRs), wherein the CDRs comprise the amino acid sequence set forth below:
For the heavy chain:
CDR1
(SEQ ID No. 33)
CDR2
(SEQ ID No. 34)
CDR3
(SEQ ID No. 35)
For the light chain:
CDR1
(SEQ ID No. 36)
CDR2
(SEQ ID No. 37)
CDR3
(SEQ ID No. 38).
2. An antibody or binding fragment thereof according to claim 1 , wherein the light chain variable region comprises SEQ ID NO. 32 and/or wherein the heavy chain variable region comprises SEQ ID NO. 30.
3. An antibody according to claim 2 , wherein the light chain comprises SEQ ID No. 31 and/or wherein the heavy chain comprises SEQ ID No. 29.
4. A diagnostic kit comprising the antibody or binding fragment according to claim 1 or an immunoconjugate thereof, and instructions for the use thereof to detect cells presenting misfolded human FasR.
5. An immunoconjugate comprising the antibody or binding fragment according to claim 1 , conjugated with a toxin or a detectable label.
6. An immunoconjugate comprising the antibody or binding fragment defined by claim 2 conjugated to a toxin or a detectable label.
7. An immunoconjugate comprising the antibody defined by claim 3 of conjugated to a toxin or a detectable label.
8. A pharmaceutical composition comprising the antibody or binding fragment according to claim 1 , or an immunoconjugate thereof, and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising the antibody or binding fragment of claim 2 , or an immunoconjugate thereof, and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the antibody of claim 3 , or an immunoconjugate thereof, and a pharmaceutically acceptable carrier.
11. A method for detecting, in a biological sample, cells that present misfolded FasR, the method comprising incubating the sample with the antibody or binding fragment according to claim 1 or an immunoconjugate thereof, and detecting formation of an antibody-bound complex.
12. A method for detecting, in a biological sample, cells that present misfolded FasR, the method comprising incubating the sample with the antibody or binding fragment according to claim 2 or an immunoconjugate thereof, and detecting formation of an antibody-bound complex.
13. A method for detecting, in a biological sample, cells that present misfolded FasR, the method comprising incubating the sample with the antibody according to claim 3 or an immunoconjugate thereof, and detecting formation of an antibody-bound complex.